Farside CV relabelling [RSABE / ABEL]

posted by d_labes  – Berlin, Germany, 2010-11-09 11:42 (5301 d 22:30 ago) – Posting: # 6118
Views: 13,881

Dear Helmut,

❝ Well, I have no idea what Pharsight calculated here ...


Me too. Their formula given on the slide
  +1.25(sigmaRef/0.25)
is clearly nonsense. It would give negative lower bounds!
The correct one is
  exp(+log(1.25)*sigmaRef/0.25)
I think.

Taking the numbers for the widened acceptance ranges given, they seems to have a label problem.
(In German: Wo 35% draufsteht sollte auch 35% drin sein!)
Label their CV=35% with 30%, their CV=40% with 35% and so on and you have perfect coincidence with your values within rounding error :cool:.
Eventually one should remind the author of the slides that labelling falls under the policy of GMP :-D.

Full ACK to all other of your points.

BTW:
<nitpicking> ------------------
I get for the FDA's widened limits:

  CV
 30%  76.95 - 129.96
 35%  73.83 - 135.45
 40%  70.90 - 141.04
 45%  68.16 - 146.71
 50%  65.60 - 152.45
 55%  63.20 - 158.23
 60%  60.96 - 164.04

using R-2.12.0 64bit on my new Intel Core i3 machine with Windows 7 Prof.
</nitpicking> ------------------ :wink:

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
161 visitors (0 registered, 161 guests [including 11 identified bots]).
Forum time: 11:13 CEST (Europe/Vienna)

A statistical analysis, properly conducted, is a delicate dissection of
uncertainties, a surgery of suppositions.    Micheal J. Moroney

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5